BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23295344)

  • 1. Downregulation of fumarate hydratase is related to tumorigenesis in sporadic renal cell cancer.
    Ha YS; Chihara Y; Yoon HY; Kim YJ; Kim TH; Woo SH; Yun SJ; Kim IY; Hirao Y; Kim WJ
    Urol Int; 2013; 90(2):233-9. PubMed ID: 23295344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
    Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
    Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
    Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
    PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of cancer in patients with fumarate hydratase germline mutation.
    Lehtonen HJ; Kiuru M; Ylisaukko-Oja SK; Salovaara R; Herva R; Koivisto PA; Vierimaa O; Aittomäki K; Pukkala E; Launonen V; Aaltonen LA
    J Med Genet; 2006 Jun; 43(6):523-6. PubMed ID: 16155190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
    Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
    Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
    Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
    Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
    Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
    Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
    Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.
    Smit DL; Mensenkamp AR; Badeloe S; Breuning MH; Simon ME; van Spaendonck KY; Aalfs CM; Post JG; Shanley S; Krapels IP; Hoefsloot LH; van Moorselaar RJ; Starink TM; Bayley JP; Frank J; van Steensel MA; Menko FH
    Clin Genet; 2011 Jan; 79(1):49-59. PubMed ID: 20618355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma.
    Ylisaukko-oja SK; Cybulski C; Lehtonen R; Kiuru M; Matyjasik J; Szymañska A; Szymañska-Pasternak J; Dyrskjot L; Butzow R; Orntoft TF; Launonen V; Lubiñski J; Aaltonen LA
    Eur J Hum Genet; 2006 Jul; 14(7):880-3. PubMed ID: 16639410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
    Sudarshan S; Pinto PA; Neckers L; Linehan WM
    Nat Clin Pract Urol; 2007 Feb; 4(2):104-10. PubMed ID: 17287871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
    Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
    Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
    Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI
    Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
    Ooi A; Wong JC; Petillo D; Roossien D; Perrier-Trudova V; Whitten D; Min BW; Tan MH; Zhang Z; Yang XJ; Zhou M; Gardie B; Molinié V; Richard S; Tan PH; Teh BT; Furge KA
    Cancer Cell; 2011 Oct; 20(4):511-23. PubMed ID: 22014576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
    Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
    Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE
    Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced L/B/K alkaline phosphatase gene expression in renal cell carcinoma: plausible role in tumorigenesis.
    Sharma U; Pal D; Singh SK; Kakkar N; Prasad R
    Biochimie; 2014 Sep; 104():27-35. PubMed ID: 24909115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hTERT expression in sporadic renal cell carcinomas.
    Paradis V; Bièche I; Dargère D; Bonvoust F; Ferlicot S; Olivi M; Lagha NB; Blanchet P; Benoît G; Vidaud M; Bedossa P
    J Pathol; 2001 Sep; 195(2):209-17. PubMed ID: 11592100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced fumarate hydratase-deficient renal cell carcinoma responding to combination immune checkpoint inhibitors.
    Howells E; Wigston L; Mackie G; Tran B; Nott L
    Can J Urol; 2023 Jun; 30(3):11558-11561. PubMed ID: 37344468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.